

## TotalSeq™-B0002 anti-mouse CD8a Antibody

<b>Catalog# / Size</b>	100783 / 10 µg
<b>Clone</b>	53-6.7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T8, Lyt2, Ly-2
<b>Isotype</b>	Rat IgG2a, κ
<b>Barcode Sequence</b>	TACCCGTAATAGCGT
<b>Description</b>	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA
<b>Preparation</b>	The antibody was purified by chromatography and conjugated with TotalSeq™-B oligomer under optimal conditions.
<b>Concentration</b>	0.5 mg/mL
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">PG - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> and the oligomer sequence is confirmed by sequencing. TotalSeq™-B antibodies are compatible with 10x Genomics Single Cell Gene Expression <a href="#">Solutions</a> .

To maximize performance, it is strongly recommended that the reagent be titrated for each application, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2 - 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to the cell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent for titration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™ protocol for specific staining instructions.

Buyer is solely responsible for determining whether Buyer has all intellectual property rights that are necessary for Buyer's intended uses of the BioLegend TotalSeq™ products. For example, for any technology platform Buyer uses with TotalSeq™, it is Buyer's sole responsibility to determine whether it has all necessary third party intellectual property rights to use that platform and TotalSeq™ with that platform.

<b>Application Notes</b>	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes <sup>3</sup> . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a <sup>+</sup> cells. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,3</sup> , <i>in vivo</i> and <i>in vitro</i> cell depletion <sup>2,10,15</sup> , inhibition of CD8 T cell proliferation <sup>3</sup> , blocking of cytotoxicity <sup>3,4</sup> , immunohistochemical staining <sup>5,6</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded
--------------------------	--

sections, and spatial biology (IBEX)<sup>29,30</sup>. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

#### Additional Product Notes

TotalSeq™ reagents are designed to profile protein levels at a single cell level following an optimized protocol similar to the CITE-seq workflow. A compatible single cell device (e.g. [10x Genomics Chromium System and Reagents](#)) and sequencer (e.g. Illumina analyzers) are required. Please contact [technical support](#) for more information, or visit [biolegend.com/totalseq](#).

The barcode flanking sequences are GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNN (PCR handle), and NNNNNNNNGCTTTAAGGCCGGTCCTAGC\*A\*A (capture sequence). N represents either randomly selected A, C, G, or T, and \* indicates a phosphorothioated bond, to prevent nuclease degradation.

View more applications data for this product in our [Scientific Poster Library](#).

#### Application References

(PubMed link indicates BioLegend citation)

1. Ledbetter JA, et al. 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology*. 3.4.1. (Deplete)
3. Takahashi K, et al. 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, et al. 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, et al. 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, et al. 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, et al. 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, et al. 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, et al. 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, et al. 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, et al. 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, et al. 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, et al. 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, et al. 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, et al. 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, et al. 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, et al. 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, et al. 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, et al. 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, et al. 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, et al. 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, et al. 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, et al. 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, et al. 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, et al. 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, et al. 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

RRID

AB\_2832269 (BioLegend Cat. No. 100783)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, CD8α chain, 34 kD
<b>Distribution</b>	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
<b>Function</b>	Co-receptor for TCR
<b>Ligand/Receptor</b>	MHC class I molecule
<b>Antigen References</b>	<ol style="list-style-type: none"><li>1. Barclay A, et al. 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li><li>2. Zamoyska R. 1994. <i>Immunity</i> 1:243.</li><li>3. Ellmeier W, et al. 1999. <i>Annu. Rev. Immunol.</i> 17:523.</li></ol>
<b>Gene ID</b>	<a href="#">12525</a>

## Related Protocols

---

[TotalSeq™-B or -C with 10x Feature Barcoding Technology](#)

## Other Formats

---

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GoInVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587